Infectious disease Archives

News and Trends 15 Aug 2016

Gilead licenses Danish Bispecific antibodies for the next HIV Cure

As an add-on to their previously secretive partnership, Genmab is now licensing its bispecific antibodies for Gilead‘s pursuit of an HIV cure for as much as €248M. At the top of the Pyramid of European Biotech value, Genmab is one of the success stories in Copenhagen’s Biotech ecosystem. Its technology for innovative antibodies has allowed it […]

August 15, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 4 Aug 2016

Roche drops Partnership for Hepatitis Immunotherapy

While everybody wants to get the next immunotherapy on the market, Roche is turning its back on one. It’s leaving the partnership with Inovio, which focuses on developing a DNA-based immunotherapy to treat Hepatitis B. Previously, Roche has left projects to focus on immunotherapies, particularly in the hype field of immuno-oncology. This was an important […]

August 4, 2016 - 3 minutesmins - By Denise Neves Gameiro

cambridge famin C13orf31 macrophage metabolism

News and Trends 3 Aug 2016

Mysterious Immunology Mechanism Unlocked thanks to CRISPR

While studying a mutation connected to inflammatory disease, researchers from the University of Cambridge have found a previously unknown mechanism in immune response. As the cost of NGS plummets, genetic data is growing massively. With the help of bioinformatics, information about genetic variants and mutations can be linked to diseases. Sophia Genetics (Switzerland), Diploid (Belgium) […]

August 3, 2016 - 3 minutesmins - By Denise Neves Gameiro

microbiome therapies seres therapeutics ser 009

News and Trends 2 Aug 2016

Microbiome Therapies suffer setback with a Phase II Failure

The hype field of the Microbiome could be taking a step back, as the most advanced program has failed to meet its primary endpoint in a Phase II trial. What does this mean for the emerging class of therapies? As we have seen at Refresh’s Microbiome fireside chat, the field took really big steps in its recent […]

August 2, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 1 Aug 2016

Biotech producer of Vaccines goes public on Nasdaq Stockholm

After raising €2M in its successful IPO, ExpreS2ion Biotech starts trading on Nasdaq First North in Stockholm – a real milestone for this industrial spin-out. Expres2ion Biotech started out in 2010, as a spin-out of a Danish company focused on human antibodies, Affitech. Affitech itself has had a convoluted path. It was initially Norwegian, then merging with […]

August 1, 2016 - 2 minutesmins - By Denise Neves Gameiro

oxitec aedes aegypti grand cayman zika dengue

News and Trends 1 Aug 2016

The Cayman Islands will now also release GM Mosquitoes against Zika Virus

A court finally allowed the release of Oxitec‘s ‘friendly’ mosquitoes in the Grand Cayman (1 of the 3 islands). If the technique repeats its recent successes, the local population of Zika-transmitting species could decrease by 90%. Located in the tropics, the Cayman Islands are one of the territories at risk of the spread of Aedes […]

August 1, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 28 Jul 2016

World Hepatitis Day 2016: What is the plan for Biotech and Policy Makers?

What is the purpose of the #NoHep campaign? To get rid of the inflammatory Liver viruses which are responsible for killing up to 1.4 million people each year, by 2030. Sometimes also described as the ‘Silent Epidemic’, Hepatitis is the inflammation of the liver, which can be caused by several types of viral infections. Research […]

July 28, 2016 - 2 minutesmins - By Dani Bancroft

nootkatone evolva natural mosquito repellant zika

News and Trends 27 Jul 2016

SynBio Nootkatone now in trials to stop the Spread of Zika

The grapefruit aroma nootkatone is now in field trials to assess its effectiveness against mosquitoes that spread the Zika virus. Good news for Evolva, which figured out a SynBio process to produce the compound. Recently, the Zika went from being considered a mild virus to a public health emergency. As the virus was linked with infant microcephaly, there […]

July 27, 2016 - 3 minutesmins - By Denise Neves Gameiro

liver hepatitis c gilead vaccine HCV metavax

News and Trends 27 Jul 2016

New Vaccine could solve the problem of the costly Gilead’s Hepatitis C ‘Cure’

Artes Biotechnology and Burnet Institute will join their proprietary technologies to develop a novel vaccine for the Hepatitis C virus. This could create a more affordable solution to reduce the high HCV-related mortality. Hepatitis C remains a health problem around the world. WHO estimates that more than half a million people die every year from […]

July 27, 2016 - 3 minutesmins - By Denise Neves Gameiro

micreos eczema mrsa infection dermatitis antibiotic biotech

News and Trends 25 Jul 2016

Eczema could also be caused by Superbugs, so how could this Biotech fight it?

A new study has shown that on average, 70% of eczema patients are colonised with Staphylococcus aureus bacteria on their skin lesions (which include MRSA). Could this the Dutch biotech Micreos therefore have the solution to preventing spread of antibiotic-resistant strains in Eczema patients? Atopic dermatitis (eczema) is an extremely common skin affliction which can cause in painful lesions, […]

July 25, 2016 - 3 minutesmins - By Dani Bancroft

cell medimmune influenza a antibody biotech

News and Trends 21 Jul 2016

‘Winner Antibody’ holds promise as universal Influenza A Vaccine

MedImmune and Humabs have reasons to be happy. Their candidate for an Influenza A vaccine has made it into well-known journal, Cell, boasting a unique affinity to the virus with multiple mechanisms to stop infection. The promising candidate is MEDI8852, an antibody initially developed by Humabs (Switzerland). It targets Influenza A virus (the group of viruses known as avian flu), […]

July 21, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 21 Jul 2016

Former uniQure and Evotec CEO pushes new viral candidate into Clinical Trials

Hookipa is starting its first clinical trial for a vaccine against human cytomegalovirus. This is the leading candidate of its platform for novel viral vectors, which promises to yield better vaccines for infections and cancer. Based in Vienna, Hookipa was founded in 2011 and is developing a new class of immunotherapies. Its strategy for novel […]

July 21, 2016 - 2 minutesmins - By Denise Neves Gameiro

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us